WallStSmart

Abbott Laboratories (ABT)vsSandisk Corp (SNDK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 242% more annual revenue ($45.13B vs $13.18B). SNDK leads profitability with a 34.2% profit margin vs 13.9%. ABT trades at a lower P/E of 24.8x. SNDK earns a higher WallStSmart Score of 70/100 (B).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

SNDK

Strong Buy

70

out of 100

Grade: B

Growth: 7.3Profit: 10.0Value: 4.0Quality: 6.8
Piotroski: 4/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-27.8%)

Margin of Safety

-27.8%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued

Intrinsic value data unavailable for SNDK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$154.45B9/10

Large-cap with strong market position

SNDK6 strengths · Avg: 10.0/10
Market CapQuality
$278.63B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
32.7%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
34.2%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
70.0%10/10

Strong operational efficiency at 70.0%

Revenue GrowthGrowth
251.0%10/10

Revenue surging 251.0% year-over-year

EPS GrowthGrowth
618.0%10/10

Earnings expanding 618.0% YoY

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

SNDK3 concerns · Avg: 3.3/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

P/E RatioValuation
64.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.32 suggests the stock is reasonably priced for its growth.

Bull Case : SNDK

The strongest argument for SNDK centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 34.2% and operating margin at 70.0%. Revenue growth of 251.0% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : SNDK

The primary concerns for SNDK are Price/Book, Altman Z-Score, P/E Ratio. A P/E of 64.1x leaves little room for execution misses.

Key Dynamics to Monitor

ABT profiles as a value stock while SNDK is a growth play — different risk/reward profiles.

SNDK is growing revenue faster at 251.0% — sustainability is the question.

SNDK generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SNDK scores higher overall (70/100 vs 56/100), backed by strong 34.2% margins and 251.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Sandisk Corp

TECHNOLOGY · COMPUTER HARDWARE · USA

Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.

Visit Website →

Want to dig deeper into these stocks?